Ypsomed Holding AG provided earnings guidance for the year ending March 31, 2015. For the year, the company expects further increase in both revenue and operating profit after the strong performance in the previous year. Revenue in the year through March 31, 2015 is expected to grow by 10% while earnings before interest and tax (EBIT) would jump by about 40% on the year.

The growth outlook is based on three contracts for injection systems signed with GlaxoSmithKline, Palatin Technologies and Pharmstandard.